Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-07-03-Speech-2-593-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-07-03"^^xsd:date2
dcterms:Is Part Of	lp_eu:EU-Israel agreement on conformity assessment and acceptance of industrial products (debate)2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20120703.23.2-593-000"2
lpv:hasSubsequent	lp_eu:2012-07-03-Speech-2-594-0002
lpv:speaker	lp:Emer Costello2
lpv:spoken text	"Mr President, I would like to thank the Commissioner for his clarifications today, which are useful. There are the legal issues that have been raised, and you have attempted to answer some of those, Commissioner. Then there are political and indeed – as some colleagues have said and I agree with them – policy coherence issues. On the one hand, we have the legal issues. Does the Commission consider that it has the legal authority to reject or geographically restrict the territorial scope of the agreement? What binding assurances can the Commission give Parliament that it will not accept, tacitly or otherwise, that the territorial competence of Israeli authorities covers the Palestinian Territories? There are widespread reports of circumvention of current rules governing control of Israeli settlement goods, so can the Commission clarify whether it intends to review or reinforce this, or how this ACAA should be monitored? But, at the same time, as the Commission provides the legal clarifications, I have to ask myself, irrespective of the legal arguments, is it coherent or credible for the EU to consistently and forcefully criticise the Israeli authorities? We had the motion with the oral question last month, we have the resolution that we will be voting on tomorrow, so is it coherent to pass these resolutions, on the one hand, and, on the other hand, to enhance our trade relationship through ratifying ACAA which – while I accept it is not technically an upgrading, given that it is based on the existing association agreement – in practice, does allow access for Israeli pharmaceuticals to one of the most lucrative markets in the world? I think that we have to take all of those issues into consideration."@en1
lpv:spokenAs	member; Conference of Delegation Chairs (2012-02-29--2014-06-30)3 substitute; CRIM (2012-03-28--2013-10-23)3 chair; Delegation for relations with the Palestinian Legislative Council (2012-02-29--2014-06-30)3 member; EMPL (2012-02-15--2014-06-30)3 unknown; Labour Party (2012-02-15--2014-06-30)3 member; S&D (2012-02-15--2014-06-30)3 substitute; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2012-03-06--2014-06-30)3 substitute; DEVE (2012-02-15--2014-06-30)3
lpv:unclassifiedMetadata	"Emer Costello (S&D )."1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph